Northwestern Global Health Foundation

Quidel this week provided an update on its budding molecular diagnostics business, noting that it saw "significant progress" in each of its three MDx initiatives.

This article has been updated from a previous version to correct the spelling of Quidel's AmpliVue technology. By Ben Butkus

The platform will combine immiscible phase filtration sample prep with automated amplification and detection, and is expected to have initial applications in point-of-care HIV testing in remote and resource-poor areas of the world. The company also sees the platform being used for decentralized molecular testing in more developed countries.